Targeting α7nAChR with agonists demonstrates dopaminergic neuroprotection, which is associated with the cholinergic anti-inflammatory pathway and reduces levodopa-induced dyskinesia as a potential antidyskinetic agent in PD animal models. This evidence concerns the gene CHRNA7 and drug-induced dyskinesia.